GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Morphic Holding Inc (NAS:MORF) » Definitions » Net-Net Working Capital

Morphic Holding (Morphic Holding) Net-Net Working Capital : $12.77 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Morphic Holding Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Morphic Holding's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $12.77.

The industry rank for Morphic Holding's Net-Net Working Capital or its related term are showing as below:

MORF's Price-to-Net-Net-Working-Capital is ranked better than
71.58% of 929 companies
in the Biotechnology industry
Industry Median: 4.02 vs MORF: 2.22

Morphic Holding Net-Net Working Capital Historical Data

The historical data trend for Morphic Holding's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Morphic Holding Net-Net Working Capital Chart

Morphic Holding Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial 4.42 4.26 8.64 8.53 13.65

Morphic Holding Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.25 14.87 14.17 13.65 12.77

Competitive Comparison of Morphic Holding's Net-Net Working Capital

For the Biotechnology subindustry, Morphic Holding's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Morphic Holding's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Morphic Holding's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Morphic Holding's Price-to-Net-Net-Working-Capital falls into.



Morphic Holding Net-Net Working Capital Calculation

Morphic Holding's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(704.349+0.75 * 0+0.5 * 0-25.492
-0-0)/49.7473
=13.65

Morphic Holding's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

Net-Net Working Capital(Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(658.766+0.75 * 0+0.5 * 0-19.185
-0-0)/50.0936
=12.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Morphic Holding  (NAS:MORF) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Morphic Holding Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Morphic Holding's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Morphic Holding (Morphic Holding) Business Description

Traded in Other Exchanges
Address
35 Gatehouse Drive, A2, Waltham, MA, USA, 02451
Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.
Executives
William Devaul officer: General Counsel and Secretary C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Bruce Rogers officer: Chief Scientific Officer C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Marc Schegerin officer: CFO and COO ARQULE INC, 1 WALL ST FL6, BURLINGTON MA 01803
Praveen P. Tipirneni director, officer: President and CEO C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Farrell Robert E Jr officer: VP Finance and Ops, Secretary CAMBRIDGE DISCOVERY PARK, 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Joseph P Slattery director C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Martin Edwards director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Timothy A Springer director, 10 percent owner 36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Peter Linde officer: Chief Medical Officer C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE A2, WALTHAM ME 02451
Nisha Nanda director 281 TRESSER BOULEVARD, STAMFORD CT 06901
Amir Nashat director 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p. director 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Susannah Gray director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Vikas Goyal director C/O SR ONE, LTD., 161 WASHINGTON ST., SUITE 500, EIGHT TOWER BRIDGE, CONSHOHOCKEN PA 19428
Otello Stampacchia director 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199

Morphic Holding (Morphic Holding) Headlines

From GuruFocus